News

NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST.

Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV vaccine with the potential to prevent HIV infection and treat HIV. The effectiveness of the new vaccine results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is seeking a collaboration partner for the NCI Phase 2 and 3 clinical trials for this vaccine and/or a licensing partner to bring the vaccine to market. Dr. Franchini will also discuss two other NCI technologies that further enhance the vaccine’s effectiveness:

• Improved HIV Vaccines Through Ras Activation
• Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Why Attend?
• Assess co-developing and/or licensing this technology
• Interact with the inventor, ask questions and provide feedback
• Learn how to partner with the NCI

Who should attend?
• Business development professionals
• Drug development professionals
• Biotech/pharma/academia researchers
• Investors and entrepreneurs

About the vaccine:
This new vaccine’s effectiveness in macaques results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is planning a Phase 1 clinical study on this vaccine at the NIH Clinical Center in late 2022.

What an HIV Vaccine could mean for patients – potential new standard of care:
Since 1985, the FDA approved 57 HIV therapeutics in seven HIV drug classes. The current standard of care for treating HIV infection is a daily oral treatment with antiretroviral therapeutics, which are often combined with three other HIV medications selected from at least two different HIV drug classes.

An HIV vaccine would completely change the current way HIV infections are addressed. For uninfected individuals, the HIV vaccine would protect them from contracting the disease. For infected individuals, it would substantially improve their quality of life by:
• Providing a potential cure, rather than treating symptoms
• Eliminating the virus, rather than suppressing it
• Providing a prime/boost treatment regimen for a finite amount of time, rather than lifelong daily dosing

Visit the link here for additional information and to register.

Recent News

07/22/2021

First Two Patients Dosed in HemoShear Therapeutics Phase 2 Study

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, dosed the first two patience in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks to

07/19/2021

Phlow Corp. Receives HHS Small Business Prime Contractor of the Year Award

The U.S. Department of Health and Human Services (HHS), recently awarded Phlow Corp. the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during

07/15/2021

VCU Health Will Anchor Redevelopment of Former Richmond Public Safety Building

As reported online by the Richmond Times Dispatch, VCU Health will anchor a new venture by Capital City Partners in downtown Richmond’s Public Safety Building at 500 N. 10th Street. The conclusion comes four months after the Richmond City Council unanimously agreed to sell the nearly 70-year-old building for $3.5 million. Capital City Partners said